Weight Loss Revolution: Meet Zepbound, FDA's New Approval for Long-term Management
In a groundbreaking move, the Food and Drug Administration (FDA) has greenlit Eli Lilly's latest drug, Zepbound, for the treatment of Type 2 Diabetes under the brand name Mounjaro. In an even more significant leap, the FDA has also authorized its use for prolonged weight control. This is a significant milestone for a medication frequently utilized off-label for weight reduction.
Who's the Ideal Candidate for Zepbound?
Adults who are overweight or have a Body Mass Index (BMI) exceeding 30 are prime candidates for Zepbound. It is also suggested for individuals with obesity (BMI 27 or higher) and those with weight-related medical issues such as hypertension, sleep apnea, or cardiovascular diseases.
Unveiling Zepbound's Magic
Zepbound works its charm by boosting the release of Insulin by mimicking two hormones: GLP-1 and GIP. It suppresses appetite and decelerates digestion post-meals, thereby making the user feel full. Medications popular for weight loss, like Semaglutid-based Wegovy from Novo Nordisk, primarily target GLP-1.
Zepbound Debuts with Six Strengths
Available in six potencies, from 2.5 mg to 15 mg, the medication can be obtained on prescription at both brick-and-mortar and online pharmacies, as per Eli Lilly's press statement.
Prescription and Usage Tips
Like other weight loss drugs, Zepbound is an injection administered once a week. Eli Lilly recommends pairing the medication with a calorie-restricted diet and increased physical activity.
Precautions, Precautions, Precautions
Eli Lilly emphasizes the avoidance of combining Zepbound with other weight-loss drugs, such as Ozempic and Wegovy.
Triumphant Trials
Higher doses of Zepbound in clinical trials led to an average weight loss exceeding 20% over 72 weeks, surpassing other authorized weight-loss medications' values.
Potential Hiccups
Common side effects include digestive issues such as nausea, vomiting, constipation, and stomach pain. Serious issues may include thyroid complications and gallbladder difficulties. For a comprehensive list, consult your healthcare provider.
Cost, Cost, Cost
Without insurance, Zepbound might set you back around $1,060 per month, just slightly above Mounjaro's list price of $1,023 per month. Rest assured, Eli Lilly has planned to release a savings card for commercial insurance holders, reducing the cost for eligible patients to $25 per month.
Supply and Demand Challenge
The demand for weight-loss therapies is soaring, yet some treatments encounter supply shortages. Currently, Mounjaro remains on the FDA's drug shortage list but is indicated as available for all dosage strengths.
Don't Miss Out on the Health Scene
Subscribe to our weekly CNN Health newsletter, curated by Dr. Sanjay Gupta, to stay updated on the latest news, features, and trending topics.
